Low Prevalence of Neurocognitive Impairment in Early Diagnosed and Managed HIV-Infected Persons
Neurol 80:371-379, Crum-Cianflone, N.,et al, 2013
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
Intracranial Mass Lesions in AIDS:Using Decision Analysis to Determine the Effectiveness of Stereotactic Brain Biopsy
Neurol 46:1010-1015, Holloway,R.G.,et al, 1996
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
Primary Central Nervous System Lymphoma
Ann Int Med 119:1093-1104, Fine,H.A.&Mayer,R.J., 1993
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
The COVID-19 Pandemic and the Ethical Duties of the Neurologist
Neurol 95:167-172, Rubin, M.A.,et al, 2020
Postherpetic Neuralgia
NEJM 371:1526-1533, Johnson, R.W.,et al, 2014
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Impact of Interferon Beta-1A On Neurologic Disability in Relapsing Multiple Sclerosis
Neurol 49:358-363, Rudick,R.A.,et al, 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Seizure Disorder
Ciba Clin Symposia 46:4-34, Devinsky,O., 1994
Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025
Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
Brain Tumors in Children
NEJM 386:1922-1931, Cohen, A.R., 2022
Spina Bifida
NEJM 387:444-450, Iskandar, B.J. & Finnell, R.H., 2022
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Benefits of Emergency Departments Contribution to Stroke Prophylaxis in Atrial Fibrillation
Stroke 48:1344-1352, Coll-Vinent, B.,et al, 2017
Subarachnoid Hemorrhage
NEJM 377:257-266, Lawton, M.T. & Vates, G.E., 2017
Surgery for Drug-Resistant Epilepsy in Children
NEJM 377:1639-1647, Dwivedi, R.,et al, 2017
Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache
Neurol 86:1818-1826, Simpson, D.M.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Resective Epilepsy Surgery for Drug-Resistant Focal Epilepsy
JAMA 313:285-293, Jobst, B.C. & Cascino, G.D., 2015
Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Ann Neurol 74:679-687, Krueger, D.A.,et al, 2013
Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy
JAMA 307:922-930,966,985, Engel,J.,et al, 2012
Substitution Monotherapy with Levetiracetam vs Older Antiepileptic Drugs
Arch Neurol 69:1563-1571, Hakami, T.,et al, 2012
Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy
JAMA 307:922-930, Engel, J.,et al, 2012
OnabotulinumtoxinA Improves Quality of Life and Reduces Impact of Chronic Migraine
Neurol 77:1465-1472, Lipton, R.B.,et al, 2011
Generic Substitution in the Treatment of Epilepsy: Case Evidence of Breakthrough Seizures
Neurol 71:525-530, Berg,M.J.,et al., 2008
Epilepsy Surgery for Pharmacoresistant Temporal Lobe Epilepsy: A Decision Analysis
JAMA 300:2497-2505,2548, Choi,H.,et al, 2008
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
Quality of Life in Patients with Charcot-Marie-Tooth Disease
Neurol 65:922-924, Vinci,P.,et al, 2005
Brain Metastases
The Neurologist 10:31-46, Klos,K.J.&O'Neill,B.P., 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Recent Developments in Bell's Palsy
BMJ 329:553-557, Holland,N.J. & Weiner,G.M., 2004
A 48-Year-Old Man With Temporal Lobe Epilepsy and Psychiatric Illness
JAMA 290:381-392, Devinsky,O., 2003
Quality of Life, Anxiety, and Depression in Patients With an Untreated Intracranial Aneurysm or Arteriovenous Malformation
Stroke 33:440-443, van der Schaaf,I.C.,et al, 2002
Physician Advice, Patient Actions, and Health-Related Quality of Life in Secondary Prevention of Stroke Through Diet and Exercise
Stroke 33:565-571,570, Greenlund,K.J.,et al, 2002
Disability and Quality of Life in Charcot-Marie-Tooth Disease Type 1
JNNP 70:548-550, Pfeiffer,G.,et al, 2001
A Randomized, Controlled Trial of Surgery for Temporal-Lobe Eiplepsy
NEJM 345:311-318,365, Wiebe,S.,et al, 2001
Vagus Nerve Stimulation Therapy for Epilepsy in Older Adults
Neurol 54:1179-1182, Sirven,J.I.,et al, 2000
Functional Outcome and Quality of Life After Angiography and Operation for Unruptured Intracranial Aneurysms
JNNP 68:571-576, Raaymakers,T.W.M., 2000
Changes in Resource Use and Outcomes for Patients with Migraine Treated with Sumatriptan, A Managed Care Perspective
Arch Int Med 159:857-863, Lofland,J.H.,et al, 1999
Patient-Oriented Outcome Assessment After Temporal Lobectomy for Refractory Epilepsy
Neurol 53:687-694, 662, Gilliam,F.,et al, 1999
When to Start and Stop Anticonvulsant Therapy in Children
Arch Neurol 56:1073-1077, Greenwood,R.S.&Tennison,M.B., 1999
Six-Month Evaluation of Carbatrol (Extended-Release Carbamazepine) in Complex Partial Seizures
Neurol 519:1727-1729, Mirza,W.U.,et al, 1998